Background: Celiac disease is an autoimmune and gluten-induced enteropathy with a worldwide prevalence of around 1%. The only proven treatment is strict and lifelong adherence to a gluten-free diet (1). Although dietary adherence is crucial for mucosal healing and prevention of long-term complications, complete avoidance of gluten is difficult for even the most committed patients. Nondietary treatments for celiac disease have no established efficacy.

Objective: To report what we believe to be the first case of serologic and histologic remission of adult celiac disease with tofacitinib despite a gluten-containing diet.

Case Report: A male patient with a histologically and serologically ...

References

  • 1. Rubin JE Crowe SE Celiac disease. Ann Intern Med2020;172:ITC1-ITC16. [PMID: 31905394]. doi:10.7326/AITC202001070 LinkGoogle Scholar
  • 2. Sandborn WJ Su C Sands BE et alOCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med2017;376:1723-36. [PMID: 28467869] doi:10.1056/NEJMoa1606910 CrossrefMedlineGoogle Scholar
  • 3. Yokoyama S Perera PY Waldmann TA et alTofacitinib, a Janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol2013;33:586-94. [PMID: 23269601] doi:10.1007/s10875-012-9849-y CrossrefMedlineGoogle Scholar
  • 4. Gilhar A Etzioni A Paus R Alopecia areata. N Engl J Med2012;366:1515-25. [PMID: 22512484] doi:10.1056/NEJMra1103442 CrossrefMedlineGoogle Scholar
  • 5. Corazza GR Andreani ML Venturo N et alCeliac disease and alopecia areata: report of a new association. Gastroenterology1995;109:1333-7. [PMID: 7557104] CrossrefMedlineGoogle Scholar